Group 1 - The core point of the news is that Zhaoyan New Drug's stock price dropped by 5.05% to 36.09 CNY per share, with a trading volume of 569 million CNY and a turnover rate of 2.45%, resulting in a total market capitalization of 27.044 billion CNY [1] - Zhaoyan New Drug Research Center Co., Ltd. specializes in non-clinical safety evaluation services for drugs, with its main business revenue composition being 95.59% from non-clinical research services, 4.34% from clinical services, and 0.07% from experimental model supply [1] - The company was established on February 25, 1998, and was listed on August 25, 2017, located in Beijing Economic and Technological Development Zone [1] Group 2 - Among the top ten circulating shareholders of Zhaoyan New Drug, Huabao Fund's Huabao CSI Medical ETF (512170) reduced its holdings by 2.1693 million shares in the third quarter, now holding 12.4838 million shares, which accounts for 1.67% of the circulating shares [2] - The estimated floating loss for Huabao CSI Medical ETF today is approximately 23.9689 million CNY [2] - The fund was established on May 20, 2019, with a current scale of 25.263 billion CNY, and has achieved a year-to-date return of 4.77% and a one-year return of 14.49% [2]

Core Viewpoint - The actual controller of Zhaoyan New Drug, Zhou Zhiwen, has terminated his plan to reduce shareholdings in the company, having sold a total of 14,979,000 shares within a specified period, resulting in significant cash proceeds. Group 1: Shareholding and Reduction Plan - Zhou Zhiwen held 74,725,981 shares before the reduction plan, representing 9.9704% of the total share capital [1] - The reduction plan was first disclosed on December 30, 2025, allowing for a maximum reduction of 14,980,000 shares, which is 20.0466% of his holdings and 1.99873% of the total share capital [1] - The actual reduction occurred from January 22 to January 28, 2026, with a total of 14,979,000 shares sold [2] Group 2: Financial Details of the Reduction - The shares were sold at a price range of 34.78 to 42.19 yuan per share, resulting in total proceeds of 567,606,657.9 yuan [1][2] - The reduction was completed with only 1,000 shares remaining unsold, achieving a reduction ratio of 1.99894% [2] - Following the reduction, Zhou Zhiwen's remaining shareholding is 59,746,981 shares, which is 7.9732% of the total share capital [2] Group 3: Historical Context - Since November 5, 2020, Zhou Zhiwen has cumulatively reduced his holdings by 14,113,200 shares, realizing approximately 915 million yuan in cash [2] - The actual controllers of Zhaoyan New Drug are identified as Feng Yuxia and Zhou Zhiwen, a couple [3]

Core Viewpoint - The actual controller of Zhaoyan New Drug (06127), Zhou Zhiwen, announced a share reduction plan, intending to reduce his holdings by up to 14.98 million shares, which represents 20.0466% of his total shares and 1.99873% of the company's total share capital [1] Summary by Sections - **Share Reduction Plan**: Zhou Zhiwen disclosed a plan to reduce his holdings by a maximum of 14.98 million shares through centralized bidding or block trading on the Shanghai Stock Exchange within three months after the announcement [1] - **Execution of the Plan**: As of January 29, 2026, Zhou Zhiwen had reduced his holdings by 14.979 million shares using block trading and centralized bidding methods, and he decided to terminate the reduction plan ahead of schedule [1]

Core Viewpoint - The company, Zhaoyan New Drug (603127), announced a share reduction plan by its actual controller, Zhou Zhiwen, which involves selling up to 14.98 million shares, representing 20.0466% of his holdings and 1.99873% of the company's total share capital [1] Summary by Relevant Sections - **Share Reduction Plan**: Zhou Zhiwen disclosed a plan to reduce his holdings starting from December 30, 2025, allowing for a period of three months post-announcement to sell shares through the Shanghai Stock Exchange [1] - **Execution of the Plan**: As of January 29, 2026, Zhou Zhiwen successfully reduced his holdings by 14.979 million shares through block trades and competitive bidding, and subsequently decided to terminate the reduction plan ahead of schedule [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 JOINN LABORATORIES (CHINA) CO., LTD. 北京昭衍新藥研究中心股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6127） 海外監管公告 本公告乃北京昭衍新藥研究中心股份有限公司（「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 北京昭衍新藥研究中心股份有限公司 关于股东提前终止减持 A 股股份计划暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 馮宇霞 董事長 中 ...

证券代码：603127 证券简称：昭衍新药 公告编号：2026-005 北京昭衍新药研究中心股份有限公司 关于股东提前终止减持 A 股股份计划暨减持结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 2025 年 12 月 30 日披露减持计划公告前，北京昭衍新药研究中心股份有限公 司（以下简称"公司"）实际控制人之一周志文持有公司股票 74,725,981 股，占公 司总股本 9.9704%，其持有的股份来源于首发前限售股份及公司资本公积金转增 股份等。 减持计划的实施结果情况 周志文于 2025 年 12 月 30 日披露了减持计划，自减持计划公告之日起 15 个 交易日后的 3 个月内通过上海证券交易所以集中竞价或大宗交易的方式减持不 超过 14,980,000 股,不超过其持有股份的 20.0466%，不超过公司当时总股本的 1.99873%。截至 2026 年 1 月 29 日，周志文以大宗交易及集中竞价交易的方式减 持公司 A 股股份 14,979,000 股，并 ...

Core Viewpoint - The company announced that one of its actual controllers, Zhou Zhiwen, reduced his holdings in the company's A-shares by a total of 14,979,000 shares, which represents approximately 1.99894% of the company's current total share capital. The reduction plan has been terminated ahead of schedule [1]. Summary by Relevant Sections - **Share Reduction Details** - Zhou Zhiwen executed the share reduction from January 22 to January 28, 2026, through centralized bidding and block trading methods [1]. - The total number of shares reduced was 14,979,000 [1]. - **Impact on Company Capital** - The reduction accounts for nearly 2% of the company's total share capital, indicating a significant change in ownership structure [1].

证券之星消息，1月27日医疗服务板块较上一交易日下跌1.13%，昭衍新药领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002524 | 光正眼科 | 5.56 | 10.10% | 117.70万 | | 6.09亿 | | 600568 | ST中珠 | 2.79 | 3.72% | 43.82万 | | 1.22亿 | | 688796 | 百奧賽图 | 70.86 | 3.14% | 2.81万 | | 1.96 (Z | | 920670 | 数字人 | 19.44 | 3.02% | 5.51万 | | 1.06亿 | | 002173 | 创新医疗 | 28.82 | 2.27% | 56.09万 | | 15.69 Z | | 301201 | 诚达药业 | 41.58 | 2.16% | 5.43万 | | 2.26亿 | | 6 ...

Core Viewpoint - Zhaoyan New Drug (603127) is forecasting a significant increase in net profit for 2025, driven by the appreciation of biological assets, particularly experimental monkeys, despite an expected decline in revenue compared to 2024 [1] Group 1: Financial Performance - The company expects to achieve operating revenue between 1.573 billion to 1.738 billion yuan, a decrease of approximately 13.9% to 22.1% compared to 2024 [1] - Net profit is projected to be between 233 million to 349 million yuan, representing an increase of approximately 214% to 371% from 2024 [1] - The forecasted non-recurring net profit is estimated at 246 million to 370 million yuan, indicating a substantial increase of approximately 945.2% to 1467.7% compared to 2024 [1] Group 2: Asset Valuation and Losses - The market fair value of the company's biological assets is expected to positively impact net profit by approximately 452 million to 499 million yuan due to price increases and natural growth [1] - The laboratory services and other business segments are anticipated to incur losses ranging from 130 million to 206 million yuan [1] Group 3: Market Dynamics - The primary biological asset contributing to the profit increase is experimental monkeys, with price increases expected to occur in the second half of 2025, although specific percentage increases are not yet available [1]

Core Viewpoint - Zhaoyan New Drug has announced a significant increase in its 2025 annual performance forecast, with a minimum increase of 945% in net profit excluding non-recurring items, despite a projected decrease in revenue [1][2]. Group 1: Financial Performance - The company expects to achieve an operating income of approximately 1.573 billion to 1.738 billion yuan in 2025, representing a decrease of about 13.9% to 22.1% compared to 2024 [2]. - The projected net profit for 2025 is estimated to be between 233 million to 349 million yuan, an increase of approximately 214% to 371% year-on-year [2]. - The net profit excluding non-recurring items is expected to be between 246 million to 370 million yuan, reflecting an increase of approximately 945.2% to 1467.7% compared to 2024 [2]. Group 2: Asset Valuation and Pricing - The increase in net profit is attributed to the positive change in the fair market value of biological assets, contributing approximately 452 million to 499 million yuan to net profit [2]. - The biological assets primarily consist of experimental models used for non-clinical research, with a significant price increase expected in the second half of 2025 [3]. - The average procurement price for non-human primate experimental animals reached a high of 150,000 to 200,000 yuan per unit in the second half of 2022, but declined to 70,000 to 100,000 yuan per unit by the second half of 2024 [3]. Group 3: Shareholder Actions - Following the strong performance of the stock, the actual controller of Zhaoyan New Drug, Zhou Zhiwen, has initiated a share reduction plan, having already sold over 10 million shares for more than 370 million yuan [1][4]. - As of January 26, 2026, the closing price of Zhaoyan New Drug was 41.39 yuan, with a market capitalization of approximately 31.02 billion yuan [4]. - Zhou Zhiwen plans to reduce his holdings by up to 14.98 million shares, which is about 1.99873% of the total share capital [4].